LAVA Therapeutics Announces Collaboration with Merck to Evaluate LAVA-1207 in Combination with KEYTRUDA January 31, 2024
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs January 31, 2024
2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Ph 2b/3 announced January 31, 2024
FAILED TRIAL: Ph 3 EVOKE-01 study did not meet primary endpoint of OS in previously treated metastatic NSCLC January 31, 2024
Complete Remission Of The Cohort 1 First Patient Treated For R/R B-ALL In Ph 1 Trial Of PMB-CT01 (BAFFR-CAR T Cells) announced January 31, 2024
Opdivo + CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in 1L Advanced RCC January 31, 2024
KEYTRUDA Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery January 31, 2024
KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With RCC at an Increased Risk of Recurrence Following Nephrectomy January 31, 2024
Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed R/R Multiple Myeloma January 31, 2024
BLA accepted for obecabtagene autoleucel (obe-cel) as a potential treatment for R/R Adult B-cell ALL January 31, 2024
